HC Wainwright Has Optimistic Outlook of Nicox Q1 Earnings

Nicox SA (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Nicox in a report released on Tuesday, January 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.04) for the quarter, up from their prior estimate of ($0.05). HC Wainwright also issued estimates for Nicox’s Q2 2026 earnings at ($0.04) EPS and Q3 2026 earnings at $0.11 EPS.

Separately, Zacks Research raised shares of Nicox to a “hold” rating in a report on Friday, October 10th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Nicox Price Performance

NICXF opened at $0.30 on Thursday. Nicox has a twelve month low of $0.25 and a twelve month high of $0.30. The company has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.29.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.